Zenidolol

Zenidolol (ICI-118551) is a selective β2 adrenergic receptor antagonist. Zenidolol inhibits β2-, β1- and β3-adrenergic receptor with Ki values of 0.7, 49.5 and 611 nM, respectively. Zenidolol can be used as an ocular hypotensive agent used for ophthalmic disease research[1].

[1]Hoffmann C, et al. Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 2004 Feb;369(2):151-9.bioRxiv. 2024 Feb 19.|J Endocrinol. 2023 Feb 16;256(3):e220335.|Nat Commun. 2023 May 2;14(1):2523.|Adv Sci (Weinh). 2024 Sep 4:e2402393.|Biochem Biophys Res Commun. 2024 Feb 15, 149689.|Biomed Pharmacother. 2023 Mar 15;161:114523.|bioRxiv. 2020 Jan.|BMC Ophthalmol. 2021 Dec 5;21(1):419.|BMC Cancer. 2019 Nov 26;19(1):1142.|Br J Pharmacol. 2020 Jan;177(2):282-297. |Cancer Discov. 2024 Aug 13.|Commun Biol. 2021 Dec 3;4(1):1359.|Commun Biol. 2022 Apr 8;5(1):339.|Diabetes. 2022 May 1;71(5):921-933.|Environ Toxicol. 2023 Dec 2.|Eur J Pharmacol. 2022 Jun 20;175110.|Int Dent J. 2024 Jul 22:S0020-6539(24)00166-7.|Int J Biol Sci. 2023 Apr 2,19.|J Exp Clin Cancer Res. 2019 Apr 25;38(1):174. |J Exp Med. 2023 Nov 6;220(11):e20230577.|J Nutr Biochem. 2018 May 1;58:110-118.|J Oral Maxillofac Surg. 2020 Oct;78(10):1871.e1-1871.e23.|J Pharm Anal. 2024 Jan 4.|Mol Oncol. 2022 May 20.|Nat Commun. 2020 Sep 25;11(1):4857.|Nat Commun. 2021 Nov 26;12(1):6937.|Neuroscience. 2019 Mar 1;401:59-72. |Oncol Rep. 2016 Sep;36(3):1576-84. |Pflugers Arch. 2021 Sep 26.|Research Square Preprint. 2020 Oct.|Research Square Preprint. 2021 Feb.|Research Square Preprint. 2021 Nov.|Research Square Preprint. 2021 Sep.|Research Square Preprint. 2022 Mar.|Sci Adv. 2024 Jul 19;10(29):eadp5239.